T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
ASP Isotopes
ASPI
$448M
| $603K | ﹤0.01% |
96,913
+16,272
| +20% | +$95.8K |
|
2527
Bowman Consulting
BWMN
$738M
| $603K | ﹤0.01% |
20,647
+2,431
| +13% | +$76.6K |
|
2528
Custom Truck One Source
CTOS
$2.15B
| $603K | ﹤0.01% |
50,999
+10,211
| +25% | +$96.2K |
|
2529
Keros Therapeutics
KROS
$230M
| $601K | ﹤0.01% |
56,121
+10,245
| +22% | +$114K |
|
2530
Compass Diversified
CODI
$846M
| $600K | ﹤0.01% |
56,201
+10,117
| +22% | +$110K |
|
|
GRDN
2531
Guardian Pharmacy Services
GRDN
$2.61B
| $600K | ﹤0.01% |
14,323
-1,841
| -11% | -$71.3K |
|
2532
GCM Grosvenor
GCMG
$797M
| $599K | ﹤0.01% |
48,632
+4,913
| +11% | +$53.7K |
|
2533
MarineMax
HZO
$1.16B
| $599K | ﹤0.01% |
16,350
+3,339
| +26% | +$107K |
|
2534
Dave & Buster's
PLAY
$231M
| $599K | ﹤0.01% |
52,509
+8,380
| +19% | +$99.8K |
|
2535
Prime Medicine
PRME
$526M
| $599K | ﹤0.01% |
162,325
+28,570
| +21% | +$94.9K |
|
|
RC
2536
Ready Capital
RC
$220M
| $599K | ﹤0.01% |
341,782
+53,343
| +18% | +$93.7K |
|
2537
SmartFinancial
SMBK
$860M
| $599K | ﹤0.01% |
12,752
+1,455
| +13% | +$61.8K |
|
2538
Marcus & Millichap
MMI
$1.13B
| $596K | ﹤0.01% |
19,101
+685
| +4% | +$19.6K |
|
|
ARX
2539
Accelerant Holdings
ARX
$4.29B
| $596K | ﹤0.01% |
+50,853
| New | +$714K |
|
|
INGM
2540
Ingram Micro Holding
INGM
$6.21B
| $595K | ﹤0.01% |
21,672
+11,130
| +106% | +$313K |
|
2541
Myriad Genetics
MYGN
$399M
| $594K | ﹤0.01% |
103,949
+12,899
| +14% | +$58.5K |
|
2542
ThredUp
TDUP
$296M
| $593K | ﹤0.01% |
86,435
+18,008
| +26% | +$84.2K |
|
2543
Rigel Pharmaceuticals
RIGL
$900M
| $592K | ﹤0.01% |
15,113
+3,257
| +27% | +$100K |
|
|
JBIO
2544
Jade Biosciences
JBIO
$917M
| $590K | ﹤0.01% |
26,546
+3,968
| +18% | +$82.8K |
|
2545
FRP Holdings
FRPH
$405M
| $590K | ﹤0.01% |
23,589
+321
| +1% | +$7.27K |
|
2546
Rush Enterprises Class B
RUSHB
$6.44B
| $590K | ﹤0.01% |
11,565
+2,692
| +30% | +$125K |
|
2547
Geron
GERN
$810M
| $589K | ﹤0.01% |
459,584
+69,568
| +18% | +$98K |
|
2548
Southern Missouri Bancorp
SMBC
$796M
| $589K | ﹤0.01% |
7,720
+248
| +3% | +$17.1K |
|
2549
Xerox
XRX
$436M
| $586K | ﹤0.01% |
186,975
+39,668
| +27% | +$99K |
|
2550
Motorcar Parts of America
MPAA
$203M
| $585K | ﹤0.01% |
38,176
-4,047
| -10% | -$49K |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.